Administrative Core
行政核心
基本信息
- 批准号:10708052
- 负责人:
- 金额:$ 34.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-21 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AchievementAdjuvant RadiotherapyAdverse eventAdvocateAgeAwardChargeClinical TrialsCollaborationsColorectalCommunicationDataData AnalysesData ElementData ScientistDescriptorDisciplineElectronic MailEnsureEquilibriumEthicsEuropeEvaluationFeedbackFundingFutureGenderGenerationsGrantImageImmuneImmune responseImmune systemImmunityImmunologyImmunooncologyInfrastructureInstitutionIntellectual PropertyInvestigationLegalLinkMalignant NeoplasmsMedicineModelingMolecularMonitorNatureNeoadjuvant TherapyNewsletterPatientsPerformancePhysiciansPilot ProjectsProcessRadiationRadiation OncologyRadiation therapyRadiobiologyRadiometryRectal CancerReportingResearchResearch Project GrantsResource SharingRestRobin birdRoleRunningScientistSecureSelf AssessmentSiteSpecific qualifier valueSpecimenTissuesTrainingTraining ActivityTumor stagecandidate identificationcommunity buildingdata sharingdesignexperienceinternational centermeetingsmembermicrobiomenovelorganizational structureprogramsprospectiveradiation effectradiomicsrecruitsuccesstooltumor
项目摘要
The ROBIN Administrative Core (AC) provides administrative and communication infrastructure to the ROBIN
grant. Led by the three P.I.s, the AC is supported by an executive committee, composed by the leaders of the
Cores, of the Molecular Characterization Trial (MCT) and of the scientific projects. The AC has a prestigious
External Advisory Board (EAB), with members who represent all the disciplines and expertise relevant to this
ROBIN. A team of experienced patients advocates, completes the organizational chart. An Executive Director
will be recruited if the ROBIN is funded, in charge of maintaining communication and coordination of all ROBIN
activities. To this scope the ROBIN Tracker will be introduced, adapted from an IT tool developed at Weill Cornell
Medicine for electronic communication of activities and tasks of large grants (like SPORE or PPG). An important
role of the AC is to develop a semestral evaluation plan and share it with the EAB, and if necessary, at ad hoc
meetings when important decisions need to be made. Metrics of success will include the timely achievement of
completion of MTAs and other legal steps to enable transfer between academic institutions of research
specimens in the US, and of research data both in the US and Europe. Planned accruals to the MCT, generation
of preliminary data from the scientific projects, and successful integration of trainees within the ROBIN programs
are additional metrics of success. The iterative nature of ROBIN will also be assessed, as it is expected that the
results of the first MCT and the associated scientific projects (converged with the feedback and results from the
other centers in the ROBIN network) will inspire the design of one or more new MCT, around year 3. These new
MCT will be implemented during the last two years of the award through the existing Immunology and Radiation
Oncology Network (IRON) that will run the proposed first MCT. Another important role of the AC consists of
assessing the Cross Training Core (CTC). While metrics of success of the CTC are defined in detail in its planned
self-assessment, the AC will monitor the CTC to ensure a harmonious integration of the different disciplines and
expertise that characterize ROBIN and are indispensable to a cross training in Radiation and Immunity, the
overarching theme of this ROBIN proposal. A central duty of the AC is to identify potential collaborations within
and beyond the ROBIN network and participate in the process of actualizing the restricted fund pilot projects
program of the ROBIN network. The ROBIN newsletter proposed in the CTC, with distribution across the network
will advertise the RFA. In addition, each of the ten academic institutions involved in this ROBIN will use their
internal communication mechanisms to solicit applications. We expect the applications to be evaluated by a
committee formed by representatives of each funded ROBIN. The AC will select representation from this ROBIN,
based on the need of the committee, with consideration to ensure its diversity (gender balance, diversity of
expertise and seniority, etc.). Finally, the AC leaders will participate in the executive activities of the ROBIN
network and will be the link for bidirectional communication between this ROBIN and the rest of the network.
ROBIN管理核心(AC)为ROBIN提供管理和通信基础设施
格兰特. AC由三个PI领导,由执行委员会支持,执行委员会由以下领导人组成:
核心,分子表征试验(MCT)和科学项目。AC有一个著名的
外部咨询委员会(EAB),其成员代表与此相关的所有学科和专业知识
罗宾一个由经验丰富的病人倡导者组成的团队完成了组织结构图。执行董事
如果ROBIN得到资助,我将被招募,负责维护所有ROBIN的沟通和协调
活动为此,将引入ROBIN跟踪器,该跟踪器改编自Weill Cornell开发的IT工具
用于大型赠款(如SPORE或PPG)活动和任务的电子通信的医学。一个重要
咨询委员会的职责是制定半年度评估计划,并与行政咨询委员会共享,如有必要,
在需要做出重要决定的时候召开会议。成功的关键将包括及时实现
完成多边贸易协定和其他法律的步骤,以便在学术研究机构之间进行转让
在美国的标本,并在美国和欧洲的研究数据。MCT的计划应计费用,生成
科学项目的初步数据,以及ROBIN计划中学员的成功整合
是衡量成功的额外标准。还将评估ROBIN的迭代性质,因为预计
第一次中期试验的结果和相关的科学项目(与第二次中期试验的反馈和结果相结合)
ROBIN网络中的其他中心)将在第3年左右激发一个或多个新MCT的设计。这些新
MCT将在该奖项的最后两年通过现有的免疫学和放射学实施
肿瘤学网络(IRON)将运行拟议的第一个MCT。顾问委员会的另一个重要角色包括
交叉训练核心(CTC)。虽然气候技术中心成功的衡量标准在其计划的
在自我评估过程中,咨询委员会将监督CTC,以确保不同学科的和谐融合,
ROBIN特有的专业知识,是辐射和免疫交叉培训不可或缺的,
这是ROBIN提案的主题。AC的核心职责是确定内部的潜在合作
以及ROBIN网络之外的其他网络,并参与限制性基金试点项目的实施过程
ROBIN网络。在反恐委员会提议的ROBIN通讯,在整个网络分发
将为RFA做广告。此外,参与此次ROBIN的十个学术机构将各自使用其
内部沟通机制,以征求申请。我们希望申请书由一个
委员会由每个资助ROBIN的代表组成。AC将从这个ROBIN中选择代表,
根据委员会的需要,并考虑到确保其多样性(性别平衡、
专业知识和资历等)。最后,AC领导人将参加ROBIN的执行活动
网络,并将成为该ROBIN与网络其余部分之间双向通信的链路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Silvia C. Formenti其他文献
Emerging evidence for adapting radiotherapy to immunotherapy
适应免疫疗法的放疗新证据
- DOI:
10.1038/s41571-023-00782-x - 发表时间:
2023-06-06 - 期刊:
- 影响因子:82.200
- 作者:
Lorenzo Galluzzi;Molykutty J. Aryankalayil;C. Norman Coleman;Silvia C. Formenti - 通讯作者:
Silvia C. Formenti
Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?
- DOI:
10.1186/s40425-016-0133-1 - 发表时间:
2016-05-17 - 期刊:
- 影响因子:10.600
- 作者:
Sandra Demaria;Silvia C. Formenti - 通讯作者:
Silvia C. Formenti
Radiosensitivity of skin fibroblasts from patients with aids-related Kaposi's sarcoma
- DOI:
10.1016/0360-3016(93)90929-p - 发表时间:
1993-01-01 - 期刊:
- 影响因子:
- 作者:
Colin K. Hill;Silvia C. Formenti;Linda Y. Chak;Parkash S. Gill;Alexandra M. Levine;Zbigniew Petrovich - 通讯作者:
Zbigniew Petrovich
Optimizing the Tumor Response to Ionizing Radiation and Immunotherapy by Blocking VEGF
- DOI:
10.1016/j.ijrobp.2008.06.524 - 发表时间:
2008-09-01 - 期刊:
- 影响因子:
- 作者:
Karsten A. Pilones;Silvia C. Formenti;Sandra Demaria - 通讯作者:
Sandra Demaria
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
- DOI:
10.1186/s40425-016-0191-4 - 发表时间:
2016-12-01 - 期刊:
- 影响因子:10.600
- 作者:
Sonja Althammer;Keith Steele;Marlon Rebelatto;Tze Heng Tan;Tobias Wiestler;Guenter Schmidt;Brandon Higgs;Xia Li;Li Shi;Xiaoping Jin;Joyce Antal;Ashok Gupta;Koustubh Ranade;Gerd Binning;Joaquim Bellmunt;Ronald de Wit;David J. Vaughn;Yves Fradet;Jae Lyun Lee;Lawrence Fong;Nicholas J. Vogelzang;Miguel A. Climent;Daniel P. Petrylak;Toni K. Choueiri;Andrea Necchi;Winald Gerritsen;Howard Gurney;David I. Quinn;Stéphane Culine;Cora N. Sternberg;Yabing Mai;Markus Puhlmann;Rodolfo F. Perini;Dean F. Bajorin;Padmanee Sharma;Margaret K. Callahan;Emiliano Calvo;Joseph W. Kim;Filipo de Braud;Patrick A. Ott;Petri Bono;Rathi N. Pillai;Michael Morse;Dung T. Le;Matthew Taylor;Pavlina Spilliopoulou;Johanna Bendell;Dirk Jaeger;Emily Chan;Scott J. Antonia;Paolo A. Ascierto;Delphine Hennicken;Marina Tschaika;Alex Azrilevich;Jonathan Rosenberg;Ofer Levy;Christopher Chan;Gady Cojocaru;Spencer Liang;Eran Ophir;Sudipto Ganguly;Amir Toporik;Maya Kotturi;Tal Fridman Kfir;Benjamin M. Murter;Kathryn Logronio;Liat Dassa;Ling Leung;Shirley Greenwald;Meir Azulay;Sandeep Kumar;Zoya Alteber;Xiaoyu Pan;Arthur Machlenkin;Yair Benita;Andrew W. Drake;Ayelet Chajut;Ran Salomon;Ilan Vankin;Einav Safyon;John Hunter;Zurit Levine;Mark White;Rom Leidner;Hyunseok Kang;Robert Haddad;Neil H. Segal;Lori J. Wirth;Robert L. Ferris;F. Stephen Hodi;Rachel E. Sanborn;Thomas F. Gajewski;William Sharfman;Dan McDonald;Shivani Srivastava;Xuemin Gu;Penny Phillips;Chaitali Passey;Tanguy Seiwert;Tsadik Habtetsion;Gang Zhou;Donastas Sakellariou-Thompson;Cara Haymaker;Caitlin Creasy;Mark Hurd;Naohiro Uraoka;Jaime Rodriguez Canales;Scott Koptez;Patrick Hwu;Anirban Maitra;Chantale Bernatchez;Scott M. Coyle;Kole T. Roybel;Levi J. Rupp;Stephen P. Santoro;Stephanie Secrest;Michael Spelman;Hanson Ho;Tina Gomes;Tiffany Tse;Chia Yung-Wu;Jack Taunton;Wendell Lim;Peter Emtage;Tarsem Moudgil;Carmen Ballesteros-Merino;Traci Hilton;Christopher Paustian;Rom Leidner;David Page;Walter Urba;Bernard Fox;Bryan Bell;Ashish Patel;Tove Olafsen;Daulet Satpayev;Michael Torgov;Filippo Marchioni;Jason Romero;Ziyue Karen Jiang;Charles Zamilpa;Jennifer S. Keppler;Alessandro Mascioni;Fang Jia;Chen-Yu Lee;Jean Gudas;Ryan J. Sullivan;Yujin Hoshida;Theodore Logan;Nikhil Khushalani;Anita Giobbie-Hurder;Kim Margolin;Joanna Roder;Rupal Bhatt;Henry Koon;Thomas Olencki;Thomas Hutson;Brendan Curti;Shauna Blackmon;James W. Mier;Igor Puzanov;Heinrich Roder;John Stewart;Asim Amin;Marc S. Ernstoff;Joseph I. Clark;Michael B. Atkins;Howard L. Kaufman;Jeffrey Sosman;Sabina Signoretti;David F. McDermott;Abraham A. Anderson;Igor Puzanov;Mohammed M. Milhem;Robert H. I. Andtbacka;David Minor;Kevin S. Gorski;Daniel M. Baker;Omid Hamid;Howard L. Kaufman;Emmanuel Akporiaye;Brendan Curti;Yoshinobu Koguchi;Rom Leidner;Kim Sutcliffe;Kristie Conder;Walter Urba;Thomas Marron;Nina Bhardwaj;Linda Hammerich;Fiby George;Seunghee Kim-Schulze;Tibor Keler;Tom Davis;Elizabeth Crowley;Andres Salazar;Joshua Brody;Arta Monjazeb;Megan E. Daly;Jonathan Riess;Tianhong Li;William J. Murphy;Karen Kelly;Zhiwei Hu;Rulong Shen;Amanda Campbell;Elizabeth McMichael;Lianbo Yu;Bhuvaneswari Ramaswam;Cheryl A. London;Tian Xu;William Carson;Kathleen M. Kokolus;Elizabeth A. Repasky;Todd D. Schell;Joseph D. Drabick;David J. Messenheimer;Shawn Jensen;Bernard Fox;Mark Rubinstein;Kristina Andrijauskaite;Marzena Swiderska-syn;Kristin Lind;Agnes Choppin;Marina K. Roell;John Wrangle;Kristina Andrijauskaite;Marzena Swiderska-syn;Peter Rhode;Hing Wong;Mark Rubinstein;Shamim Ahmad;Mason Webb;Rasha Abu-Eid;Rajeev Shrimali;Vivek Verma;Atbin Doroodchi;Zuzana Berrong;David Yashar;Raed Samara;Mikayel Mkrtichyan;Samir Khleif;Steven Powell;Mark Gitau;Christopher Sumey;Andrew Terrell;Michele Lohr;Ryan K. Nowak;Steven McGraw;Ash Jensen;Miran Blanchard;Kathryn A. Gold;Ezra E. W. Cohen;Christie Ellison;Lora Black;John Lee;William Chad Spanos;Erik Wennerberg;Emily Schwitzer;Claire Lhuillier;Graeme Koelwyn;Rebecca Hiner;Lee Jones;Sandra Demaria;Vandeveer Amanda;John W. Greiner;Jeffrey Schlom;Michelle Bookstaver;Christopher M. Jewell;Christopher Paustian;Andrew Gunderson;Brian Boulmay;Rui Li;Bradley Spieler;Kyle Happel;Tarsem Moudgil;Zipei Feng;Carmen Ballesteros-Merino;Christopher Dubay;Brenda Fisher;Yoshinobu Koguchi;Sandra Aung;Eileen Mederos;Carlo B. Bifulco;Michael McNamara;Keith Bahjat;William Redmond;Augusto Ochoa;Hong-Ming Hu;Adi Mehta;Fridtjof Lund-Johansen;Bernard Fox;Walter Urba;Rachel E. Sanborn;Traci Hilton;Frank Bedu-Addo;Greg Conn;Michael King;Panna Dutta;Robert Shepard;Mark Einstein;Sylvia Adams;Ena Wang;Ping Jin;Yelena Novik;Debra Morrison;Ruth Oratz;Franco M. Marincola;David Stroncek;Judith Goldberg;Sandra Demaria;Silvia C. Formenti;Jérôme Galon;Bernhard Mlecnik;Florence Marliot;Fang-Shu Ou;Carlo B. Bifulco;Alessandro Lugli;Inti Zlobec;Tilman T. Rau;Iris D. Nagtegaal;Elisa Vink-Borger;Arndt Hartmann;Carol Geppert;Michael H. Roehrl;Prashant Bavi;Pamela S. Ohashi;Julia Y. Wang;Linh T. Nguyen;SeongJun Han;Heather L. MacGregor;Sara Hafezi-Bakhtiari;Bradley G. Wouters;Yutaka Kawakami;Boryana Papivanova;Mingli Xu;Tomonobu Fujita;Shoichi Hazama;Nobuaki Suzuki;Hiroaki Nagano;Kiyotaka Okuno;Kyogo Itoh;Eva Zavadova;Michal Vocka;Jan Spacek;Lubos Petruzelka;Bohuslav Konopasek;Pavel Dundr;Helena Skalova;Toshihiko Torigoe;Noriyuki Sato;Tomohisa Furuhata;Ichiro Takemasa;Marc Van den Eynde;Anne Jouret-Mourin;Jean-Pascal Machiels;Tessa Fredriksen;Lucie Lafontaine;Bénédicte Buttard;Sarah Church;Pauline Maby;Helen Angell;Mihaela Angelova;Angela Vasaturo;Gabriela Bindea;Anne Berger;Christine Lagorce;Prabhu S. Patel;Hemangini H. Vora;Birva Shah;Jayendrakumar B. Patel;Kruti N. Rajvik;Shashank J. Pandya;Shilin N. Shukla;Yili Wang;Guanjun Zhang;Giuseppe V. Masucci;Emilia K. Andersson;Fabio Grizzi;Luigi Laghi;Gerardo Botti;Fabiana Tatangelo;Paolo Delrio;Gennaro Cilberto;Paolo A. Ascierto;Franco Marincola;Daniel J. Sargent;Bernard A. Fox;Alain Algazi;Katy Tsai;Michael Rosenblum;Prachi Nandoskar;Robert H. I. Andtbacka;Amy Li;John Nonomura;Kathryn Takamura;Mary Dwyer;Erica Browning;Reneta Talia;Chris Twitty;Sharron Gargosky;Jean Campbell;Carmen Ballesteros-Merino;Carlo B. Bifulco;Bernard Fox;Mai Le;Robert H. Pierce;Adil Daud;Robyn Gartrell;Douglas Marks;Edward Stack;Yan Lu;Daisuke Izaki;Kristen Beck;Dan Tong Jia;Paul Armenta;Ashley White-Stern;Yichun Fu;Zoe Blake;Howard L. Kaufman;Bret Taback;Basil Horst;Yvonne M. Saenger;Steven Leonardo;Keith Gorden;Ross B. Fulton;Kathryn Fraser;Takashi O. Kangas;Richard Walsh;Kathleen Ertelt;Jeremy Graff;Mark Uhlik;Jennifer S. Sims;Liang Lei;Takashi Tsujiuchi;Jeffrey N. Bruce;Peter Canoll;Anthony W Tolcher;Evan W Alley;Gurunadh Chichili;Jan E Canoll;Paul Moore;Ezio Bonvini;Syd Johnson;Sadhna Shankar;James Vasselli;Jon Wigginton;John Powderly - 通讯作者:
John Powderly
Silvia C. Formenti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Silvia C. Formenti', 18)}}的其他基金
PSMA/MR-guided Stereotactic Body Radiotherapy for High Risk Prostate Cancer
PSMA/MR 引导的立体定向放射治疗高危前列腺癌
- 批准号:
10440533 - 财政年份:2020
- 资助金额:
$ 34.33万 - 项目类别:
GammabeamX200 Preclinical Research Irradiator
GammabeamX200 临床前研究辐照器
- 批准号:
7795491 - 财政年份:2010
- 资助金额:
$ 34.33万 - 项目类别:
CLINICAL TRIAL: INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHAR
临床试验:基于肿瘤分子碳的乳腺癌个体化治疗
- 批准号:
7718400 - 财政年份:2008
- 资助金额:
$ 34.33万 - 项目类别:
BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER
双周紫杉醇
- 批准号:
7605686 - 财政年份:2007
- 资助金额:
$ 34.33万 - 项目类别:
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS
基于肿瘤分子特征的乳腺癌个体化治疗
- 批准号:
7605704 - 财政年份:2007
- 资助金额:
$ 34.33万 - 项目类别:
RESPONSE, RESISTANCE AND METASTASIS OF LOCALLY-ADVANCED BREAST CANCER (LABC)
局部晚期乳腺癌 (LABC) 的反应、抵抗和转移
- 批准号:
7605773 - 财政年份:2007
- 资助金额:
$ 34.33万 - 项目类别:
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS
基于肿瘤分子特征的乳腺癌个体化治疗
- 批准号:
7378275 - 财政年份:2006
- 资助金额:
$ 34.33万 - 项目类别:
BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER
双周紫杉醇
- 批准号:
7378246 - 财政年份:2006
- 资助金额:
$ 34.33万 - 项目类别:
相似海外基金
Randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer
在分子特征低风险 Luminal A 早期乳腺癌患者中进行辅助放疗与保乳手术和内分泌治疗后观察的随机 III 期试验
- 批准号:
nhmrc : GNT1099899 - 财政年份:2016
- 资助金额:
$ 34.33万 - 项目类别:
Project Grants
Randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer
在分子特征低风险 Luminal A 早期乳腺癌患者中进行辅助放疗与保乳手术和内分泌治疗后观察的随机 III 期试验
- 批准号:
nhmrc : 1099899 - 财政年份:2016
- 资助金额:
$ 34.33万 - 项目类别:
Project Grants
The evaluation of late adverse effects of adjuvant radiotherapy using in silico sarrogate end marker
计算机辅助放疗晚期不良反应评价
- 批准号:
15K19760 - 财政年份:2015
- 资助金额:
$ 34.33万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
A trial of surgery versus surgery plus adjuvant radiotherapy in patients with resected nodal metastatic melanoma.
对切除的淋巴结转移性黑色素瘤患者进行手术与手术加辅助放疗的试验。
- 批准号:
nhmrc : 251732 - 财政年份:2003
- 资助金额:
$ 34.33万 - 项目类别:
NHMRC Project Grants